Surprisingly, we found that higher ERBB3 mRNA levels predict a significantly shorter RFS in basal-like breast cancer patients (Figure 1a), whereas no significant correlation was observed in other breast cancer subtypes (Figure 1b–d). This evidence concerns the gene ERBB3 and breast cancer.